Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.
Mattia D'Agostino, MD
Advertisement
Articles by Mattia D'Agostino, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Multi-Omic Profiling Reveals Genetic and Epigenetic Pirtobrutinib Resistance Pathways in MCL
5